Mindmed appoints francois lilienthal, md as chief commercial officer

- dr. lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology - new york , april 5, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of francois lilienthal, md as chief commercial officer. with more than two decades of global biopharmaceutical experience and after serving as a consultant for mindmed over the past six months, dr. lilienthal will step into this role to support the advancement of the company's clinical development programs.
MNMD Ratings Summary
MNMD Quant Ranking